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ABSTRACT
Objectives The success of B cell targeting therapies
has highlighted the importance of B cells in rheumatoid
arthritis pathogenesis. We have previously shown that B
cells in the RA synovium are capable of producing pro-
inﬂammatory and bone-destructive cytokines including
RANKL. Here we sought to characterise the nature and
functional relevance of the RANKL-producing B cell
subset in the RA synovium.
Methods Synovial ﬂuid and peripheral blood B cells
from patients with RA were analysed by ﬂow cytometry
for markers of B cell differentiation and activation and
for chemokine receptors. FcRL4+ and FcRL4− B cells
sorted from synovial ﬂuid were analysed for cytokine
expression using Taqman low-density arrays. Synovial
tissue biopsies obtained from patients with RA were
analysed by immunoﬂuorescence for CD20, RANKL and
FcRL4. FCRL4 mRNA expression was determined in
synovial tissue of RA patients and non-inﬂammatory
control subjects by real-time PCR.
Results RANKL-producing B cells in RA synovial tissue
and ﬂuid were identiﬁed as belonging to a distinct
subset of B cells deﬁned by expression of the
transmembrane protein FcRL4. FcRL4+ B cells express a
distinct combination of cytokines and surface proteins
indicating a function distinct from that of FcRL4− B
cells. Notably, FcRL4+ B cells expressed high levels of
TNF-α and RANKL mRNA.
Conclusions We have identiﬁed a novel pro-
inﬂammatory B cell population in the RA synovium
which is deﬁned by expression of FcRL4 and responsible
for RANKL production. This B cell population expresses
high levels of CD20, and its removal by rituximab may
contribute to the anti-inﬂammatory effect of this drug.
INTRODUCTION
The effectiveness of B cell depleting anti-CD20
antibodies such as rituximab in reducing synovial
inﬂammation and progression of structural damage
in RA suggests B cells are critically involved in
these processes.1 2 Potential pathogenic attributes
of B cells include their ability to produce autoanti-
bodies, act as antigen presenting cells, and secrete
cytokines.3 We have recently described the produc-
tion of a range of cytokines including RANKL,
TNF-α and IL-6 by synovial B cells.4 RANKL plays
a critical role in stimulating the differentiation and
activation of bone-resorbing osteoclasts, while
pro-inﬂammatory cytokines such as TNF-α and
IL-6 contribute to erosion by stimulating
production of RANKL, directly acting on osteo-
clasts and their precursors, and stimulating matrix
metalloproteinase production by other cell
types.5–8 RANKL also has an important role in
lymphoid development with RANKL-deﬁcient mice
lacking all lymph nodes.7 Levels of RANKL in the
synovium are signiﬁcantly reduced following treat-
ment with rituximab, suggesting a link between B
cells, inﬂammation and joint destruction.9
RANKL expression has been reported in a
FcRL4 positive subset of memory B cells present in
the human tonsil.10 Fc-receptor-like-4 (FcRL4) is a
transmembrane protein with homology to Fc recep-
tors which is capable of aborting B cell receptor-
mediating signalling and proliferation, and may
therefore play an important role in the regulation
of B cell activation and differentiation.11 12
Expression of FcRL4 is restricted to B cells and
across 950 cancer cell lines is only detected in B
cell tumour lines (EBI Gene Expression Atlas).
FcRL4 is expressed predominantly in the tonsil,
with lower levels detected in the salivary gland,
spleen and tongue (EBI Gene Expression Atlas,
NCBI GeoProﬁles database). In the present study,
we have identiﬁed a subset of B cells expressing
FcRL4 in the rheumatoid synovium. This FcRL4+
B cell population is capable of producing the bone-
destructive and pro-inﬂammatory cytokines
RANKL and TNF-α, and is thus likely to represent
a pathogenic B cell subset.
METHODS
Patients
Synovial ﬂuid and peripheral blood were obtained
from patients with long-standing RA fulﬁlling 1987
American College of Rheumatology (ACR) classiﬁ-
cation criteria.13 Synovial tissue was obtained from
25 newly presenting patients with rheumatoid arth-
ritis (RA) or undifferentiated arthritis (UA) that
evolved into RA during follow-up, and eight
control subjects undergoing arthroscopy for assess-
ment of non-inﬂammatory conditions. Patient
details are provided in table 1. The study was con-
ducted in compliance with the Helsinki declaration,
and ethical approval was obtained from the local
ethics committee. All subjects gave informed,
written consent.
Flow cytometry and cell sorting
Synovial ﬂuid was incubated with 1000 U/mL
endotoxin-free hyaluronidase (Wockhardt UK) at
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37°C for 15 min. Mononuclear cells were isolated from synovial
ﬂuid and peripheral blood using density gradient centrifugation.
Cells were stained with mouse monoclonal antibodies against
CD19 (Biolegend), CD20 (Invitrogen), CD27 (BD Pharmingen),
IgD (eBioscience), CD11c (Biolegend), RANKL (eBioscience),
FcRL4 (Biolegend), CD95 (BD Pharmingen), CD21
(eBioscience), CD80 (BD Biosciences), CD86 (Biolegend),
CCR1 (R&D Systems) and CCR5 (BD Biosciences). Isotype,
concentration, species and label-matched control antibodies
were used. Data were acquired using a Dako Cyan ADP ﬂow
cytometer and analysed using SUMMIT software. Synovial ﬂuid
mononuclear cells were stained with antibodies against CD19
(Immunotools) and FcRL4 (Biolegend) and sorted using a
MoFlo cell sorter (Dako). Sorted populations had a purity of
>95%. Mononuclear cells were also isolated from mechanically
dissociated synovial tissue as previously described14 from RA
patients undergoing joint-replacement surgery which were
assessed by ﬂow cytometry for FcRL4 and CD19.
Immunoﬂuorescence
Staining was performed on 5 mm frozen tissue sections. Mouse
anti-CD20 (Dako) was developed with goat anti-mouse IgG2a
FITC (Southern Biotech), rabbit anti-RANKL (AbCam) was devel-
oped with donkey anti-rabbit Rhodamine ( Jackson
ImmunoResearch), and mouse anti-FcRL4 (BioLegend) was devel-
oped with goat anti-mouse IgG2b Cy5 (Southern Biotech).
Isotype-matched irrelevant controls were used ( Jackson
ImmunoResearch). Sections were incubated with primary antibody
for 1 h and secondary antibody for 30 min. Sections were
mounted using a DAPI-containing mounting medium. Sections
were visualised using a Zeiss confocal LSM 510 microscope and
images were processed using Zeiss LSM Image Examiner software.
Immunohistochemistry
Staining was performed on 5 mm frozen acetone-ﬁxed sections.
Endogenous peroxidase activity was blocked with Bloxall
Solution (Vector) and 2% casein was used to block non-speciﬁc
staining. Sections were washed with phosphate buffered saline
(PBS) between incubation steps. Sections were incubated with
anti-CD20 (Dako), mouse anti-FcRL4 (Biolegend), or isotype-
matched irrelevant controls ( Jackson ImmunoResearch) for 1 h,
rabbit anti-mouse Ig (Dako) for 10 min, and anti-rabbit Ig
peroxidase (Vector Laboratories) for 30 min. Staining was devel-
oped using a diaminobenzidine substrate (Vector Laboratories).
Slides were counterstained with haematoxylin and mounted
with dibutyl phthalate xylene (DPX) (Sigma Aldrich).
Real-time PCR
TaqMan low-density real-time PCR arrays (Applied Biosystems)
were designed to determine expression of the following genes:
IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-10, IL-11,
IL-12p35, IL-12p40, IL-13, IL-15, IL-17A, IL-18, IL-21, IL-22,
IL-23p19, IL-27, TNF-α, LT-β, RANKL, APRIL, BAFF, TGF-β1,
CSF-2, CSF-3, MIF, EGF, FGF2, VEGF-α, IFN-γ, IFN-α1,
IFN-β, CCL2, CCL3, CCL4, CCL5, CCL11, CXCL8, CXCL12,
GAPDH and 18S. RNA was extracted from sorted B cells
(minimum 103 cells per sample) using a Nucleospin XS kit
(Machery-Nagel). A reaction mixture containing 49 mL RNA,
50 mL Quantitect-RT Master Mix (Qiagen) and 1 μL Quantitect
Reverse Transcriptase (Qiagen) was added to a TaqMan micro-
ﬂuidic card. Reverse transcription and real-time PCR was per-
formed in a 7900HT Real-Time PCR System (Applied
Biosystems). The cycling program used was 50°C for 30 min,
94.5°C for 15 min, then 40 cycles of 96°C for 30 s and 59.7°C
for 1 min. FcRL4 expression was determined in synovial tissue
from RA patients and non-inﬂammatory controls. RNA was
extracted from 20 μm synovial tissue sections using the RNeasy
kit (Qiagen), reverse transcribed using the Superscript VILO kit
(Invitrogen), then used in real-time PCR assays containing
12.5 μL Taqman Master Mix, 1 μL FcRL4 or 18S assay (all
Applied Biosystems), 6.5 μL H2O and 5 μL cDNA. The cycling
programme used was 50°C for 2 min, 95°C for 10 min and 40
cycles of 15 s at 95 and 1 min at 60°C. Relative gene expression
(RQ) was expressed as 2−ΔCt.
Statistical analysis
The Wilcoxon-matched paired test was used to assess differences
in matched samples or cell populations. The Mann–Whitney
test was used to assess differences between two groups. The
Kruskal–Wallis test and Dunn’s post-test were used to compare
>2 groups. The Spearman correlation test was used to assess
correlation. Medians are shown on dot plots. All statistical ana-
lyses were carried out using GraphPad Prism software.
Table 1 Clinical characteristics of patients
RA patients from whom synovial fluid was obtained
Newly presenting patients with RA or UA that
evolved into RA during follow-up
from whom synovial tissue was obtained
Patients, n 23 25
Female, n (%) 15 (65) 15 (60)
Age yrs; median (IQR) 55 (44–68) 58 (47–65)
Disease duration; median (IQR) 7 years (1–11) 12 weeks (6–38)
RF-positive, n (%) 13 (57) 12 (48)
CCP-positive, n (%) 10 (53)* 14 (56)
CRP, mg/mL; median (IQR) 20 (7–45) 18 (8–42)
ESR, mm/h; median (IQR) 36 (20–43) 27 (16–57)
SJC (28); median (IQR) 4 (2–9) 7 (4–15)
TJC (28); median (IQR) 5 (2–10) 7 (3–15)
DAS28 ESR; median (IQR) 5.2 (3.6–5.6) 5.2 (4.3–6.5)
DMARDs, n receiving (%) 16 (70) 1 (4)
*CCP information was available for 19/23 patients.
CCP, cyclic citrullinated peptide; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; SJC, swollen joint count; TJC, tender joint count.
2 Yeo L, et al. Ann Rheum Dis 2014;0:1–8. doi:10.1136/annrheumdis-2013-204116
Basic and translational research
 group.bmj.com on March 6, 2014 - Published by ard.bmj.comDownloaded from 
RESULTS
Identiﬁcation of FcRL4+ B cells in the rheumatoid synovium
Analysis of matched synovial ﬂuid and peripheral blood mono-
nuclear cells from established RA patients by ﬂow cytometry
showed that RANKL-producing B cells are present in the syn-
ovial ﬂuid, and are signiﬁcantly enriched in this compartment
compared to peripheral blood (ﬁgure 1A,B). RANKL has previ-
ously been detected in tonsillar memory B cells deﬁned by
surface expression of the FcRL4 receptor. We therefore sought
to determine whether RANKL+ B cells present in RA synovial
ﬂuid belonged to the FcRL4+ B cell population. Synovial ﬂuid
and peripheral blood mononuclear cells were stained for FcRL4
and RANKL in addition to the B cell marker CD19. In the syn-
ovial ﬂuid, FcRL4 was found to be expressed by a subset of B
cells (comprising a median of 13% of B cells), and this popula-
tion was found at a signiﬁcantly higher frequency in synovial
ﬂuid compared to peripheral blood (median 0.4%) (ﬁgure 1C).
The percentage of B cells among the synovial ﬂuid mononuclear
cells ranged from 1.1% to 6.3% (median 1.3%, n=10, data not
shown). Assessment of coexpression of FcRL4 and RANKL
showed that RANKL was indeed expressed by FcLR4+ B cells,
with RANKL+ B cells found to be signiﬁcantly enriched in the
FcRL4+ B cell population compared to the FcRL4− B cell frac-
tion (ﬁgure 1D). The variability in RANKL expression by
FcRL4+ B cells may reﬂect the requirement of FcRL4+ B cells
to receive a stimulatory signal in order to express RANKL. No
signiﬁcant correlation was observed between the percentage of
FcRL4+ and/or RANKL+ B cells in synovial ﬂuid and disease
activity (ESR or DAS28 ESR).
In order to determine if FcRL4+ B cells were present in the
inﬂamed RA synovium itself, synovial tissue sections from
patients with established RA were stained for FcRL4, RANKL
Figure 1 Identiﬁcation of FcRL4+ B cells in the RA synovial ﬂuid (SF). (A) Cells were gated on a forward and side scatter pattern typical for
lymphocytes (R1). Doublets were excluded based on pulse width versus forward scatter properties (R2). (B) Flow cytometric analysis of mononuclear
cells from peripheral blood (PB) and SF shows RANKL expression by B cells is signiﬁcantly higher in SF compared with PB. (C) FcRL4 is expressed by
B cells in SF at a signiﬁcantly higher frequency than PB. (D) RANKL is expressed by FcRL4+ B cells in SF, with RANKL+ B cells signiﬁcantly enriched
in the FcRL4+ B cell population. **p<0.01, Wilcoxon paired test.
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and CD20. FcRL4− expressing B cells were detected in synovial
tissue, and these were found to express RANKL (ﬁgure 2A).
FcRL4+ B cells were predominantly localised beneath the syn-
ovial lining layer and around blood vessels (ﬁgure 2B).
Additionally, FcRL4 mRNA expression was assessed in synovial
tissue from established RA patients and non-inﬂammatory
control subjects. mRNA expression of FcRL4 was signiﬁcantly
elevated in established RA patients compared to non-
inﬂammatory controls (ﬁgure 2C). FcRL4 mRNA expression
was also upregulated in a proportion of early RA patients from
whom samples were obtained within the ﬁrst 3 months of
symptom onset (ﬁgure 2C). This indicated that FcRL4+ B cells
are not present in normal synovium but develop or accumulate
in RA. FcRL4 mRNA expression in the synovium of RA patients
signiﬁcantly correlated with ESR (p=0.03, R=0.64, ﬁgure 2D),
suggesting an association between the presence of FcRL4+ B
cells and the degree of inﬂammation. The type of leukocyte
inﬁltrate in synovial tissue samples from newly presenting
patients with RA or UA that evolved into RA during follow-up
was graded as uninﬂamed, diffuse or focal (containing
Figure 2 FcRL4 is present in the RA synovium. (A) Established RA synovial tissue stained for CD20 (green), FcRL4 (blue) and RANKL (red) using
immunoﬂuorescence. Coexpression of FcRL4 and RANKL is detected in CD20+ B cells. Image representative of n=5. (B) Localisation of FcRL4+
CD20+ B cells in established RA synovial tissue by immunohistochemistry. Representative of n=3. (C) FCRL4 mRNA expression in synovium from
non-inﬂamed controls (n=8), early RA patients (n=13) and established RA patients (n=12). FcRL4 expression is signiﬁcantly higher in RA synovium.
*p<0.05, Mann–Whitney test. (D) Correlation between FcRL4 expression and ESR in established RA patients. (E) FcRL4 expression in synovial tissue
from newly presenting RA, UA that evolved into RA during follow-up, or established RA, is highest in biopsies containing focal lymphocyte
aggregates. *p<0.05, Kruskal–Wallis test (overarching bar) and Dunn’s post-test (underlying bar).
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lymphocyte aggregates) by examining H&E-stained biopsies.
FcRL4 mRNA expression in matched biopsies was signiﬁcantly
increased in samples with focal aggregates compared to those
with diffuse leukocyte inﬁltration (ﬁgure 2E). We used ﬂow
cytometry to assess FcRL4 expression in mechanically disso-
ciated synovial tissue from established RA patients. A mean of
16% of B cells (range 8–32%) was recovered from synovial
tissue expressed FcRL4 (n=4, data not shown).
Phenotypic characterisation of synovial ﬂuid FcRL4+ B cells
The majority of the synovial ﬂuid B cells, whether they
expressed FcRL4 or not, displayed a memory B cell phenotype.
FcRL4+ B cells were mainly IgD-CD27+ switched memory B
cells (median 47%) or IgD-CD27- double-negative B cells
(median 41%) (ﬁgure 3A). Of the FcRL4− B cell fraction, a
median of 57% B cells were IgD-CD27+ and 30% were
IgD-CD27-. There was a small but statistically signiﬁcant
enrichment of CD27-IgD- and CD27-IgD+ B cells in the
FcRL4+ compared to the FcRL4− subset. Deﬁned by the IgD/
CD38 classiﬁcation system, FcRL4+ B cells were predominantly
IgD-CD38- (median 75%), which reﬂected the dominant
phenotype of all synovial ﬂuid B cells (ﬁgure 3A). RANKL+ B
cells were also mainly IgD-CD27+ and IgD-CD38− switched
memory B cells (ﬁgure 3B). Coexpression of FcRL4 and
RANKL by each of the B cell subsets deﬁned by IgD and CD27
expression is shown in online supplementary ﬁgure S1. Further
assessment of cell surface markers highlighted several pheno-
typic differences that distinguish FcRL4+ and FcRL4− synovial
ﬂuid B cells. FcRL4+ B cells expressed higher levels of CD95,
CD11c and CD20, and lower levels of CD21 in comparison
with FcRL4− B cells (ﬁgure 4). FcRL4+ B cells showed elevated
expression of the chemokine receptors CCR1 and CCR5.
FcRL4+ B cells were also found to express signiﬁcantly higher
levels of the costimulatory molecules CD80 and CD86 com-
pared with FcRL4− B cells.
Figure 3 Memory phenoytpe of FcRL4+ and RANKL+ B cells in RA synovial ﬂuid (SF). (A) Gating strategy for FcRL4+ and FcRL4− SF B cells and
IgD/CD27 or IgD/CD38 expression. (B) FcRL4+ B cells and FcRL4− B cells are mainly switched memory IgD-CD27+ and IgD-CD27− and IgD-CD38−
B cells. (C) Gating strategy for RANKL+ and RANKL− SF B cells and IgD/CD27 or IgD/CD38 expression. (D) RANKL+ B cells and RANKL− B cells are
mainly switched memory IgD-CD27+ and IgD-CD27- and IgD-CD38- B cells. Wilcoxon matched paired test, *p<0.05, **p<0.01; n=10. Box length
represents IQR; line represents median. *p<0.05, **p<0.01, Wilcoxon paired test. n=6–12.
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A pro-inﬂammatory role for FcRL4+ B cells in RA
Since FcRL4+ B cells were found to produce increased levels of
RANKL, we sought to determine whether they exhibited an
extended cytokine proﬁle that was distinct from other B cells in
the RA synovium. FcRL4+ and FcRL4− B cells were sorted from
synovial ﬂuid (as shown in ﬁgure 5A) and the expression of 43
cytokines was assayed using real-time PCR low-density arrays (see
online supplementary ﬁgure S2 for full dataset). Comparison of
FcRL4+ and FcRL4− B cells revealed that RANKL was expressed
at signiﬁcantly higher levels in the FcRL4+ B cell subset, conﬁrm-
ing the observations made by ﬂow cytometry at the protein level
(ﬁgure 5B). Notably, FcRL4+ B cells expressed signiﬁcantly
higher levels of TNF-α mRNA than the FcRL4− B cell fraction
(ﬁgure 5B). FcRL4+ and FcRL4− B cells also showed distinct
expression patterns of several other cytokines. FcRL4− B cells
showed signiﬁcantly higher expression of lymphotoxin-β, B cell
activating factor (BAFF), TGF-β, CCL3, CCL4 and CCL5 in com-
parison with FcRL4+ B cells (ﬁgure 5B).
Figure 4 Phenotypic characterisation
of FcRL4+ B cells in RA synovial ﬂuid.
FcRL4+ and FcRL4− B cells are
phenotypically distinct. FcRL4+ B cells
have higher expression of CD11c, CD20,
CD95, CD80, CD86, CCR1 and CCR5,
and lower expression of CD21 compared
to FcRL4− B cells. *p<0.05, **p<0.01,
Wilcoxon paired test; n=7–10.
Figure 5 FcRL4+ B cells represent a pro-inﬂammatory population with a unique cytokine proﬁle. (A) Gating strategy for FcRL4+ and FcRL4− B cell
fractions sorted from RA synovial ﬂuid using a MoFlo FACS sorter. Populations were sorted to a minimum purity of 95%. (B) Real-time PCR analysis
of cytokine mRNA in FcRL4+ and FcRL4− B cells shows that FcRL4+ B cell express higher levels of RANKL and TNF-α than the FcRL4− B cell
population. Conversely, FcRL4− B cells express higher levels of LT-β, B cell activating factor (BAFF), transforming growth factor-β (TGF-β), VEGF-α,
CCL3, CCL4 and CCL5. *p<0.05, **p<0.01, Wilcoxon matched paired test; n=9.
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DISCUSSION
This study identiﬁes a pro-inﬂammatory B cell population in the
inﬂamed synovium of patients with RA. This B cell subset is
deﬁned by its expression of FcRL4, and expresses signiﬁcantly
higher levels of mRNA for RANKL and TNF-α compared to
other synovial B cells. The cytokine proﬁle of the FcRL4+ B cell
subset suggests that this population may be an important driver
of chronic inﬂammation and bone destruction. TNF-α is recog-
nised as a pivotal pro-inﬂammatory cytokine in inﬂammation
and joint destruction in RA. Its pleiotropic actions include leuko-
cyte and endothelial cell activation leading to pro-inﬂammatory
cytokine production and leukocyte accumulation in the inﬂamed
synovium, as well as stimulation of metalloproteinase release by
ﬁbroblasts and chondrocytes leading to cartilage and bone
destruction.15 16 RANKL and TNF-α are important mediators of
osteoclast differentiation and activation. We therefore suggest
that the B cell subset investigated here may contribute to bone
erosion in patients with RA.
While FcRL4+ B cells are absent from the peripheral blood in
healthy individuals, they have been detected in the blood of
HIV-infected patients17 and malaria-exposed individuals18 where
they have been found to exhibit a similar set of surface markers
compared with that found in the tonsils and, as shown here, in the
rheumatoid synovium. CD11c+CD21− B cells have been
reported to accumulate in the peripheral blood of RA, systemic
lupus erythematosus (SLE) and scleroderma patients19; these may
represent a stage of B cell differentiation related to the FcRL4+ B
cell population we describe here. However, the FcRL4+ subset is
largely found in tissue, and can only rarely be identiﬁed in periph-
eral blood. It is conceivable that the CD11c+CD21− B cells may,
if they enter the inﬂamed tissue, upregulate expression of FcRL4.
The location of the FcRL4+ B cells outside the follicular clusters
of B cells is reminiscent of a B cell subset described as interfollicu-
lar B cells. This latter group has been observed in the synovium,
but beyond expression of activation-induced cytidine deaminase
(AID), an enzyme involved in immunoglobulin gene hypermuta-
tion, their role in the synovium is not yet deﬁned.20 The expres-
sion of CD80 and CD86 that we observed in FcRL4+ B cells is
consistent with the activated phenotype described for tonsillar
FcRL4+ B cells,21 and may point to a costimulatory role for
FcRL4+ B cells in the synovium. FcRL4+ B cells were found to
have elevated expression of CCR1 and CCR5 which are receptors
for the chemokines CCL3, CCL4 and CCL5 (MIP-1α, MIP-1β
and RANTES). Altered chemokine receptor expression may, there-
fore, account for the homing to and retention of FcRL4+ B cells
in the inﬂamed synovium.
The unique expression proﬁle of cytokines and chemokine
receptors, together with the location of FcRL4+ B cells in syn-
ovial tissue, suggests FcRL4+ B cells are functionally distinct
from other B cells present in the RA synovium. FcRL4+ B cells
in tonsils do not express transcription factors necessary for plas-
mablast development21; however, the contribution of FcRL4+
B cells to local autoantibody production in the rheumatoid
synovium remains to be investigated. Functional studies have
described the FcRL4 receptor as capable of attenuating signal-
ling through the B cell receptor, and also augmenting B cell acti-
vation through TLR9 signalling.11 12 22 TLR9 is an important
driver of animal models of arthritis23 and putative TLR9 ligands
such as DNA containing CpG motifs and single-stranded DNA
have been found in RA synovial ﬂuid.24 It is tempting to specu-
late that in RA FcRL4 may enhance immune activation through
activation of TLR9 or, indeed, other TLRs which are known to
be potently activated by disease-relevant ligands, such as
immune complexes containing citrullinated proteins.25 While
the functional contribution of the receptor in the RA synovium
so far remains unknown, FcRL4 may serve as a useful marker
for pro-inﬂammatory cytokine-producing B cells.
The effect of B cell targeting therapies such as rituximab cannot
be entirely explained by the reduction of autoantibody levels.26
FcRL4+ B cells express signiﬁcantly higher levels of CD20 com-
pared with other synovial B cells, and we have previously shown
that following treatment of RA patients with rituximab, levels of
RANKL in the synovium are signiﬁcantly diminished.9 Removal of
the FcRL4+ subset of B cells from the inﬂamed synovium may,
therefore, contribute to the anti-inﬂammatory and ant-ierosive
effect of rituximab. Other mechanisms, such as costimulation
inhibition and cytokine production blockade have been proposed
but have not been thoroughly investigated. It is conceivable that
removal of the cytokine and costimulatory signals produced by
FcRL4+ B cells contributes to the clinical response seen in patients
undergoing B cell depleting therapy. Current B cell depletion
therapy for RA indiscriminately removes B cells and thus has the
disadvantages of reducing patients’ responses to vaccination and
can lead to a drop in total immunoglobulin levels. We propose
that FcRL4 may represent a potential therapeutic target which
would allow speciﬁc removal of a subset of pro-inﬂammatory B
cells while leaving protective B cell immunity intact.
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